Modification of proteins by the addition of lysine (K)-63-linked polyubiquitin (polyUb) chains is suggested to play important roles in a variety of cellular events, including DNA repair, signal transduction, and receptor endocytosis. However, identifying such modifications in living cells is complex and cumbersome. We have generated a monoclonal antibody (mAb) that specifically recognizes K63-linked polyUb, but not any other isopeptide-linked (K6, K11, K27, K29, K33, or K48) polyUb or monoubiquitin. We demonstrate the sensitivity and specificity of this K63Ub-specific mAb to detect K63Ub-modified proteins in cell lysates by Western blotting and in cells by immunofluorescence, and K63Ub-modified TRAF6 and MEKK1 in vitro and ex vivo. This unique mAb will facilitate the analysis of K63-linked polyubiquitylation ex vivo and presents a strategy for the generation of similar reagents against other forms of polyUb.
MAP kinase kinase kinase 1 (MEKK1) ͉ TNF receptor-associated factor 6 (TRAF6) P osttranslational modification of proteins by ubiquitin (Ub) attachment plays an important role in diverse cellular events, including cell division, differentiation, signal transduction, protein trafficking, and quality control (1, 2) . Ub can be attached to proteins by free lysine, cysteines, or N-terminal residues by specific E3 Ub ligases (3) (4) (5) . Monoubiquitylation (the addition of a single Ub residue per targeting site) was shown to modulate protein endocytosis, intracellular transport, and DNA repair (6) (7) (8) . Monoubiquitin can be further modified to generate polyubiquitin (polyUb) chains via an isopeptide linkage between the C-terminal glycine carboxyl group of the Ub moiety being added and the -amino group of a free lysine on the protein-attached Ub (9) . Ubiquitin has 7 surface-exposed lysine residues (Fig. 1D) , and elongation to generate polyUb chains can occur on any of these residues. Indeed, all 7 types of polyUb chains have been found in cells (10, 11) (Fig. 1D ). K48-linked polyubiquitylation, associated with subsequent protein degradation by 26S proteasomes (3, 12) , is perhaps the most frequently found Ub modification (10) . However, other forms of polyUb are much more common than originally thought and are currently the subject of significant interest. K11-linked polyubiquitylation was recently suggested to mediate protein turnover (13) , whereas K29-linked Ub chains formed by the E3 ligase ITCH have been implicated in the lysosomal degradation of proteins in cells (14) . K63-linked polyubiquitylation is thought to modulate protein-protein interactions during DNA repair (6, 15, 16) , signal transduction (17) , receptor endocytosis (2) , and other cellular events (18) . Endogenous K6-, K27-, or K33-linked polyubiquitylation of protein substrates has been reported, but their functions are not clear (19) (20) (21) . In addition to linear Ub chains with homogeneous linkages, mixed or forked Ub chains containing multiple linkages have been identified, although the function of these chains is also unclear (22) (23) (24) (25) .
Recently, several novel K63-linked polyUb-specific binding partners and modifying enzymes have emerged. NZF (Npl4 zinc finger) domains have been shown to bind specifically K63-polyUb (26) , and tandem NZF domains have been used to purify K63-linked polyubiquitylated proteins (27) . Proteins with NZF domains, such as TAB2/3 and Trabid, play important roles in Toll-like receptor (TLR) and CD40-induced NF-B activation and in TCF-induced Wnt signaling (26, 27) . Furthermore, some deubiquitylating enzymes specific for the K63 polyUb linkage, such as A20, CYLD, and Ataxin-3, have recently emerged as critically important to the regulation of various cellular pathways (28) (29) (30) (31) . All of these data suggest that K63-linked polyubiquitylation of protein substrates plays vital roles and is tightly regulated in diverse cellular events. However, it is not clear how K63-linked polyUb modification mediates these events. Furthermore, it is very difficult to identify K63-linked polyubiquitylation in living cells because of the absence of a simple method for directly determining the nature of polyUb isopeptide linkage type. Three methods are currently used. First, protein ubiquitylation reactions can be performed in vitro with the target protein, an E3 Ub ligase and Ub mutants that lack 1 or several lysine residues (e.g., K63R-Ub) to restrict the type of Ub chain extension (17) . However, such reactions may not accurately reflect what occurs in cells and are likely to be promiscuous. Second, specific types of polyubiquitylation can be blocked by overexpression of Ub mutants in cells (32, 33) . However, this approach is often restricted to cell lines because it is difficult to overexpress exogenous genes in many primary cells, such T and B cells. Furthermore, such an approach can lead to saturation and sequestration of rate-limiting E2 Ub-conjugating enzymes by the overexpressed Ub mutants, which allows modification to take place with Ub-loaded E2s present at high concentrations that are not physiologically representative. Third, mass spectrometry-based technology has been used to determine the type of ubiquitylation both in vitro and ex vivo (10) . However, such procedures require high protein purity and quantity that prevent analysis of ubiquitylation in samples with either low cell number or low protein amounts. Given these limitations, new approaches and reagents need to be developed that can specifically identify different types of Ub modifications ex vivo without the need for ectopic expression or cellular modification.
Results and Discussion
Strategy for Generating K63-PolyUb-Specific Antibodies. Monoclonal antibodies (mAbs) have the capacity to distinguish subtle chemical and structural differences in their ligands. This is well illustrated by the ability of phosphopeptide-specific mAbs to recognize their specific ligands, but not the unphosphorylated peptide or a different phosphorylated peptide (34) . Our goal in this work was to apply a strategy similar to that used in developing phospho-specific antibodies to generate a mAb specific for K63-linked polyUb that did not cross-react with Ub or other types of Ub linkages. As an example, there are 2 clear differences between K63-linked and K48-linked polyUb. First, the conformation is quite different with K63-linked di-Ub having an elongated structure, whereas K48-linked di-Ub has a tightly packed, globular structure ( Fig. 1) (35) . Second, the linking isopeptide bond by definition targets a different lysine residue within the second Ub moiety, and thus the amino acid sequence motif proximal to the isopeptide bond is different. To mimic the unique microenvironment of the K63-Ub isopeptide bond, we generated a branched peptide, referred to as U63U, in which the COOH terminus of the Ub[71-76] peptide (RLRGG) was attached to the -amine of K63 in the Ub[58-66] peptide (DYNIQKEST) [ Fig. 1E and supporting information (SI) Table  S1 ]. Similarly, Ub[71-76] was linked to peptides containing the other Ub lysine residues to generate 6 branched peptide controls (Table S1 and Fig. S1 ).
The U63U branched peptide was conjugated to keyhole limpet hemocyanin (KLH) and used to immunize 5 BALB/c mice. After 3 immunizations, we collected sera and assessed reactivity to the immunogen and control peptides by ELISA. All 5 mice (termed HWA1-5) showed reactivity against the U63U branched peptide ( Fig. S2 and Tables S2 and S3). Sera from mouse HWA4 exhibited high reactivity to the U63U immunogen, but had no detectable specificity against the U48U branched peptide and the component linear peptides (Ub [58] [59] [60] [61] [62] [63] [64] [65] [66] and Ub[68-76]), and this mouse was therefore selected for fusion. Of 253 hybridomas generated, 32 had positive reactivity against the U63U branched peptide by ELISA, with 8 having stable reactivity after subcloning by limiting dilution followed by single cell flow cytometric sorting.
High Specificity of the K63-PolyUb-Specific mAb. We further tested the reactivity of the mAb produced by these clones against Ub [58] [59] [60] [61] [62] [63] [64] [65] [66] , Ub [68] [69] [70] [71] [72] [73] [74] [75] [76] , and the U48U branched peptide. Clone HWA4C4 showed high selectivity for U63U, with no detectable reactivity against the related control Ub-derived peptides or Ub protein and thus was selected for further analysis ( Fig. 2A and Tables S2 and S3 ). These data suggested that the HWA4C4 mAb (IgG2a) may specifically recognize K63-linked polyUb. To test this possibility, we first checked by ELISA and Biacore analysis the binding activity of HWA4C4 with all 7 branched peptides mimicking the isopeptide linkages of the 7 possible polyUb chains (Fig. 2 ). Both assays demonstrated HWA4C4 to be highly specific for U63U and not to cross-react with any other Ub branched peptides. HWA4C4 also exhibited reasonable affinity against its immunogen (K d ϭ 8.8 nM) and may have a sensitivity comparable with that of P4D1, a commonly used mAb that recognizes all forms of Ub (Fig. S3) .
To assess the specificity of HWA4C4 against protein targets, equal amounts of synthesized, recombinant K63-linked and K48-linked polyUb, and purified Ub were immunoblotted with purified HWA4C4. The P4D1 mAb, which recognizes all forms of Ub, was used as a control throughout. Our data clearly show that only K63-linked polyUb is recognized by HWA4C4 mAb (Figs. 3A and S4). Weak reactivity with free Ub is only observed at very high protein concentrations (30 ng of K63-linked polyUb vs. 10-30 g of Ub, a 300-to 1,000-fold difference; Fig. S4A ). Given that the K63-linked polyUb preparation contains multiple bands that constitute the total protein loaded, the actual ratio is likely to be much higher. No cross-reactivity is observed with K48-linked polyUb at any concentration (Fig. S4B) . To exclude the possibility that HWA4C4 may recognize other polyUb chains, we assessed its reactivity to in vitro-generated K6-, K11-, K27-, K29-, K33-, K48-, and K63-linked polyubiquitylated substrate ( Fig. S5 and Table S4 ). Although 3 different Ub-specific mAbs (P4D1, FK1, and FK2) and 1 Ub-specific polyclonal Ab (UG9510) all showed comparable recognition of the 7 polyubiquitylated proteins, the HWA4C4 mAb only recognized the K63-linked polyubiquitylated substrate (Figs. 3B and S5).
Two additional approaches were used to assess the specificity and sensitivity of HWA4C4 further. Ectopic expression of Ub mutants has been used to block/disrupt specific polyUb chain assemblies (16, 33) . For example, the expression of K63R-Ub, in which lysine-63 is mutated to arginine, is able to compete with endogenous WT Ub for inclusion into K63-polyUb chains and block further chain extension. To test further the specificity of HWA4C4 ex vivo, we generated HEK293T cells expressing similar levels of WT, K48R, or K63R Ub (HA-tagged), as revealed by immunoblot analysis of lysates using HA mAb. Importantly, our K63Ub-specific mAb clearly detected K63-polyUb-conjugated proteins in whole, unmanipulated lysates from WT-Ub or K48R-Ub expressing HEK293T cells (Fig. 4A) . In contrast, we observed a complete disappearance of high-molecular mass reactive bands with lysate from the K63R-Ub transfectants. The few lower-molecular mass bands still present in the K63R-Ub sample may represent nonsubstrate conjugated short K63-linked Ub chains that have not been terminated by the K63R Ub mutant. This almost complete inhibition of K63-linked polyUb chain formation in 293T cells expressing K63R-Ub provided an opportunity to assess the ability of HWA4C4 to work in immunofluorescence experiments. Although uniform staining with P4D1 was observed with both cell populations, a restricted pattern of staining with HWA4C4 was only observed with the WT Ub transfectants, but not the cells expressing K63R-Ub (Fig. S6) . Given that the K63R mutation has been shown not to affect the assembly of other lysine linked polyUb chains, these data suggest that HWA4C4 only recognizes K63-linked polyUb, but not other lysine-linked polyUb, ex vivo.
Ubc13 is a Ub-conjugating enzyme (E2) known to catalyze specifically K63-linked polyubiquitylation (15, 36) , As a further demonstration of the selective utility of our K63Ub-specific mAb, we assessed the pattern of K63-linked polyubiquitylated proteins in a short hairpin RNA (shRNA)-targeted A20 B cell transductant that lacked Ubc13 (37) . As expected, a selective loss/reduction of reactive bands was observed in lysate from Ubc13-deficient cells, demonstrating the sensitivity and specificity of HWA4C4 (Fig. 4B) . The remaining HWA4C4-reactive bands in Ubc13-deficient cell lysate support the notion that other as yet unidentified E2s can catalyze K63-linked polyubiquitylation.
Collectively, these data suggest that HWA4C4 has high selectivity for the K63Ub isopeptide linkage and specifically recognizes K63-linked polyubiquitylated proteins both in vitro and ex vivo. 
Sensitive Detection of K63-Polyubiquitylated TRAF6 in Vitro and ex
Vivo. To assess further the sensitivity and utility of our K63Ub mAb (HWA4C4) for ex vivo analysis, we examined 2 proteins known to be modified with K63-linked polyUb, TNF receptor-associated factor 6 (TRAF6) and mitogen-activated protein kinase kinase kinase 1 (MEKK1; also known as MAP3K1) (17, 38, 39) . TRAF6 is an E3 Ub ligase that contains a RING domain that can mediate K63-linked polyubiquitylation in vitro after oligomerization (17) . TRAF6 can both autoubiquitylate and mediate the ubiquitylation of other substrates. TRAF6 can also be ubiquitylated by other cellular E3 Ub ligases. We used a TRAF6-gyrase B stable cell line, in which a TAP (tandem affinity purification)-tagged TRAF6 was fused to a fragment of bacterial gyrase B such that oligomerization could be controlled by addition of coumermycin A (40) . A ubiquitylated TRAF6 ladder was efficiently detected with both the Ub mAb (P4D1) and our K63Ub mAb (HWA4C4) after oligomerization (Fig. 5A) .
Previous studies have shown that the overexpression of TRAF6 induces its K63-linked polyubiquitylation via its own RING domain (38, 41) . We used this approach to assess further the specificity of our K63Ub mAb. Whereas overexpression of a RING domain mutant of TRAF6 resulted in reduced but detectable ubiquitylation compared with wild-type TRAF6, K63-linked polyubiquitylation was abolished in the RING mutant, and thus the K63Ub mAb (HWA4C4) only recognized ubiquitylated wild-type TRAF6 (Fig.  5B) . These data suggest that HWA4C4 is capable of specifically detecting K63-linked polyubiquitylation ex vivo.
Next, we stimulated a mouse macrophage-like cell line (RAW 264.7) with a series of pathogen-associated molecular patterns that activate distinct TLRs. Activation by LPS, CpG DNA, and poly(I⅐C) resulted in rapid TRAF6 polyubiquitylation that was detected by both the Ub mAb (P4D1) and K63Ub mAb (HWA4C4) (Fig. 5C) . The extent of TRAF6 K63-linked polyubiquitylation was higher in cells activated by TLR4 (LPS) or TLR9 (CpG) than TLR3 [poly(I⅐C)]. These results are consistent with the more substantial role played by TRAF3 in TLR3 signaling relative to TLR4 and TLR9 signaling that rely mainly on TRAF6 (40) . Furthermore, under the same conditions no TRAF2 polyubiquitylation was observed in agreement with the lack of TRAF2 involvement in TLR signaling. However, TRAF2 K63-linked ubiquitylation was seen upon CD40 activation of B cells (37) .
Sensitive Detection of K63-Polyubiquitylated MEKK1 in Vitro and ex
Vivo. MEKK1 also contains a RING finger-like domain (42) , can autoubiquitylate, and in vitro can be modified with either K48-or K63-linked polyUb (39) . Although the E3 Ub ligase activity of MEKK1 was suggested to play both positive and negative roles, leading to some MEKK1 degradation after its activation (43), we have not detected receptor-induced MEKK1 degradation in CD40-stimulated cells (39) . This suggests that ex vivo, MEKK1 polyubiquitylation may be predominantly K63-linked because K48-linked polyubiquitylation may mediate proteasomal degradation. To determine the actual nature of MEKK1 modification, we first assessed the specificity of HWA4C4 toward ubiquitylated MEKK1 by performing an in vitro ubiquitylation assay with MEKK1 immunoprecipitates from anti-CD40-stimulated B cells, E1 and E2 Ubconjugating enzymes, and either WT, K63R or K48R Ub mutants (Fig. 6A) . The Ub mAb P4D1 was shown to recognize MEKK1 conjugated with all 3 recombinant Ub molecules, confirming that in vitro MEKK1 can undergo self-ubiquitylation through K63-linked, K48-linked, or other lysine-linked polyUb. As expected, our K63Ub mAb (HWA4C4) could only recognize the wild-type and K48R Ub-modified MEKK1. [The faint ladders in the K63R sample may be caused by MEKK1 being modified by endogenous Ub after B cell stimulation (Fig. 6B) (39) ].
Finally, we assessed the ability of HWA4C4 to detect endogenous MEKK1 K63-linked ubiquitylation in CD40-stimulated B cells. Importantly, both the Ub mAb (P4D1) and K63Ub mAb (HWA4C4) revealed ubiquitylated MEKK1 only after cell stimulation (Fig. 6B) . We used a variety of knockdown and mutant B cell lines to determine dependence of MEKK1 polyubiquitylation on other signaling molecules. We found that the K63-linked polyubiquitylation of MEKK1 was Ubc13-, TRAF2-and IKK␥-dependent (Fig. 6B) . Notably, Ubc13 is a K63 Ub-specific E2 whose ablation in mice prevents the activation of MAP kinases by CD40 and other immunoreceptors (44) . Knockdown of TRAF3 and TRAF6 had no effect. Interestingly, no MEKK1 ubiquitylation was detected with the Ub mAb (P4D1) in B cells lacking the K63-specific E2 Ubconjugating enzyme Ubc13, suggesting that K48-linked ubiquitylation of MEKK1 does not occur in cells. These data not only emphasize the utility, sensitivity, and specificity of our K63Ub mAb, but also serve to illustrate that promiscuous polyubiquitylation of proteins can occur in in vitro assays that may not reflect events in cells. Furthermore, the absence of the K48-linked MEKK1 polyubiquitylation in CD40-engaged B cells is consistent with our inability to detect receptor-induced MEKK1 degradation in such cells for at least 2 h after CD40 engagement (Fig. S7) . Although the results of these experiments indicate that MEKK1 K63-linked ubiquitylation is TRAF2-dependent, it should be noted that TRAF2 is required for the activation of MEKK1 protein kinase activity, which in turn is required for activation of its self-ubiquitylating activity (A.M., P.-H.T. and M.K., unpublished observations). Thus, it is not clear whether TRAF2 is directly or indirectly responsible for MEKK1 ubiquitylation. Activation of MEKK1 protein kinase activity also depends on the scaffold protein IKK␥/NEMO (37), which as shown above is also required for MEKK1 K63-linked polyubiquitylation (Fig. 6B) . 
Conclusions
The specificity of the HWA4C4 mAb demonstrates that a branched peptide is capable of mimicking the isopeptide linkage of K63-linked polyUb and can be used as an immunogen to generate a linkage-specific mAb. Specificity for polyUb but not monoUb is likely ensured by the unique structure of the isopeptide linkage between the COOH-terminal sequence of Ub and the lysine, whereas the amino acid residues around K63 make the mAb specific for the K63 polyUb chain. We demonstrate here that this antibody may be used for detection of synthesized, purified, or immunoprecipitated proteins and does not require high cell numbers or large-scale protein purification efforts. Furthermore, we also show that HWA4C4 can detect K63Ub-modified proteins in whole lysates, demonstrating that prior immunoprecipitation is not a prerequisite for its use. Although HWA4C4 does not appear to immunoprecipitate K63Ub presumably because of epitope accessibility, it can specifically detect K63Ub-modified proteins in cells by immunoprecipitation, further expanding the utility of this mAb. This represents a unique reagent/approach that can directly detect K63-linked polyubiquitylation ex vivo with minimal cellular manipulation, as has been recently demonstrated (37) . The general strategy used here may be extended to generating mAbs specific for other polyUb linkages, such as K48Ub or K29Ub, or for Ubmodified substrates, where the target substrate lysine is known, for example, K21 and K22 of IB␣ (45) or K855 of the NF-B2 precursor p100 (46) . Indeed and interestingly, a resent study has used a comparable strategy to develop an antibody specific for monoubiquitylated H2B by using a branched peptide as immunogen (47) .
Materials and Methods
Cell Lines, Antibodies, and Ub Reagents. 1.3E2 (Ikk␥ Ϫ ) and the parental cells, 70Z3 cells (Ikk␥ ϩ ), were kindly provided by Gilles Courtois, Institut National de la Santé et de la Recherche Mé dicale U697 (48) . Cells were maintained at 37°C, 5% CO2 in RPMI medium 1640 supplemented with FCS, glutamine, and antibiotics (Invitrogen). The following commercial antibodies were used: horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Amersham) and anti-rabbit IgG (Jackson Laboratories); HRP-conjugated anti-goat IgG, MEKK1, IKK␥, TRAF2, TRAF3, TRAF6, and Ubc13 Ub (all from Santa Cruz Biotechnology), HA (12CA5, gift from Linda Hendershot, St. Jude Children's Research Hospital). K48-and K63-linked polyUb were purchased from Biomol, and free Ub was from Sigma. Ubiquitylation assay reagents were obtained from Boston Biochem. Polyubiquitylated substrates are available from Biomol (details of the approach for generation of these proteins are given in SI Materials and Methods).
Synthesis of Branched Peptides. All peptides were synthesized by the Hartwell Center for Biotechnology and Bioinformatics at St. Jude Children's Research Hospital. The peptides were made by using Fmoc chemistry on a Rainin Symphony Multiplex 12-column synthesizer. To make the branched peptides, the orthogo-
NovaBiochem] was used. After the main peptides were synthesized and the N termini acetylated, the ivDdeprotecting groups on the lysine -amino groups were selectively removed by using 3 mL of 2% hydrazine for 3 min. The short peptide branches were then synthesized. After synthesis, final deprotection, and cleavage, the final peptides were purified by reverse-phase HPLC on a Beckman Biosys 500 with a Vydac C-18 column. The immunogen U63U was conjugated to KLH via the N terminus of the Ub[71-76] peptide (RLRGG) by using glutaraldehyde.
Immunization of Mice and Generation of Hybridomas. BALB/c mice (Jackson Laboratories) were immunized i.p. with KLH-conjugated U63U immunogen (20 g) in complete Freund's adjuvant. Mice were boosted twice by injection of KLH-conjugated U63U in incomplete Freund's adjuvant at 3-week intervals. Mice were bled for screening purposes at every boost and killed 72 h after the last boost before splenectomy. The splenocytes and lymph node cells were collected, mixed with X63-Ag-8.653 mouse myeloma cells at a ratio of 5:1, pelleted, and incubated with 37°C prewarmed polyethylene glycol 1500 (PEG 1500; Sigma). The cell mix was slowly and gently resuspended in 37°C prewarmed HBSS buffer. After gentle agitation for 3 min, the cell mix was pelleted, resuspended in compete tumor medium (CTM) (49, 50) and plated in 96-well plates at 10 5 splenocytes per well. After a 24-h incubation, CTM containing Hypoxanthine Aminopterin Thymidine (HAT) (Invitrogen, 50ϫ) was added to select hybrid clones. Plates were incubated at 37°C in a tissue culture incubator until visible colonies were present in the wells. The supernatants were screened twice on two subsequent occasions by ELISA, and the positive wells were subcloned by limiting dilution and single-cell sorting. The mAb isotype was determined by ELISA and was purified by using protein G affinity chromatography (Amersham).
Oligomerization and Purification of TRAF6 from TRAF6-Gyrase B Stable Cell Lines. The N terminus of TRAF6 was tagged with a tandem affinity tag consisting of a His6 element and a signature sequence for intracellular biotinylation (HBT) (21) , whereas the C terminus of TRAF6 was fused with the N-terminal fragment of bacterial gyrase B. The HBT-TRAF6-gyrase B construct was transduced into HEK293 cells. To induce dimerization of TRAF6, cells were treated with coumermycin A, and cell extracts were prepared for purification as described in ref. 40 . A tandem affinity tag-based 2-step purification under full denaturing conditions was used to purify the HBT-tagged TRAF6 (details of the purification are given in SI Materials and Methods) (21) .
Splenic B Cell Isolation and in Vitro Ubiquitylation Assay. Splenic B cells were isolated as described in ref. 39 . Splenocyte suspensions were generated by grinding spleens between 2 cover slips. CD43Ϫ B cells were isolated with magnetic beads (MACS; Miltenyi) according to manufacturer's protocol. B cells or B cell lines (1 ϫ 10 6 cells per mL) were stimulated with anti-CD40 (5 g/mL; clone 3/23; PharMingen). Washed MEKK1 immunoprecipitated complexes from splenic B cell lysates were incubated with Ub, ATP, E1 and a mixture of E2 Ub conjugating enzymes: UbcH2, UbcH3, Ubc5a, Ubc5b, Ubc5c, UbcH6, UbcH7, and UbcH10. After 30 min, reaction mixtures were separated by SDS/PAGE and analyzed by immunoblotting with Ub, K63Ub, and MEKK1 antibodies. ShRNA Constructs. Oligonucleotides directed against the indicated mRNAs were cloned into the pLSLPw lentiviral plasmid [kindly provided by Peter M. Chumakov, Cleveland Clinic (51)]. The oligonucleotide sequences used for the shRNA constructs are as follows: m/h-Ubc13, 5Ј-AATCCAGATGATCCATTAGCA (52); m-TRAF2, 5Ј-CTAGACCAGGACAAGATTG; m-TRAF3, 5Ј-GCAAGAG-AGAGATTCTGGC; m-TRAF6, 5Ј-CGTCCTTTCCAGAAGTGCC. Lentiviral packaging was performed as described, and details are provided in SI Materials and Methods (53) .
The details on Biacore analysis, ELISA, immunoblotting, immunoprecipitation, and immunofluorescent staining are provided in SI Materials and Methods.
